Despite the mildness of the dominant omicron variant and the evidence that the Pfizer COVID-19 vaccine hasn’t stopped infection or transmission of SARS-CoV-2 while posing serious health risks, the company’s CEO is asking the FDA to grant emergency use authorization for a second booster, a fourth shot.“Clearly there is a need in an environment of omicron to boost the immune response,” Albert Bourla, CEO of Pfizer, said Friday on CNBC’s “Squawk Box.”Bourla claimed the data indicate the protection against severe disease after three doses is “very good.” But the protection wanes after only three or four months, he acknowledged.In January,...